FDA recall, , Moderate risk
Lupin Pharmaceuticals Liraglutide Injection
Liraglutide Injection contains a white thread-like structure in the cartridge.
Summary by Recall Canary from the FDA notice
What happened
Lupin Pharmaceuticals Inc., of Naples, Florida, recalled Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Rx only, due to the presence of particulate matter: a white thread-like structure in the cartridge. The product, manufactured by Lupin Limited, Nagpur 441108, INDIA, was distributed nationwide within the U.S. The company began the recall on April 24, 2026.
The recall was added to the FDA's Enforcement Report on May 19, 2026, and included 217,621 pen injectors.
What to do
We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:
- Check the FDA or company notice for instructions specific to this product.
- Ask your pharmacist or doctor whether your lot is affected and what to do.
Is yours affected?
Affected if its NDC and lot code are listed under that product.
An NDC (National Drug Code) is usually printed on the drug's label.
Liraglutide Injection
- NDC
- 70748-346-02
- 70748-346-03
- Lot code
- WB00097
- WB00094
- WB00088
- WB00103
- WC00016
- WB00098
- WB00092
- WB00093
- WB00104
- WB00106
- WB00105
Recall details
- Company began the recall
- Sold in
Nationwide within U.S
- Company
- Lupin Pharmaceuticals Inc.Naples, Florida
- Hazard
- Foreign object
- Risk
Moderate risk
Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.
FDA Class II recall · How risk is rated
- Event ID
- 98809
- Recall number
- D-0541-2026
- Quantity recalled
- 217,621 pen injectors
All recalls from Lupin Pharmaceuticals Inc.
Timeline
FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.
Company began the recall
Added to FDA's Enforcement Report · Classified by FDA
Listed on Recall Canary
In FDA's weekly enforcement report
Summary updated
